Onclive Team

We traveled to Pittsburgh, Pennsylvania for a State of the Science Summit on Breast Cancer, which focused on novel approaches in metastatic triple-negative breast cancer and treatment strategies for patients with brain metastases.

John Mendelsohn, MD, president emeritus of The University of Texas MD Anderson Cancer Center and an internationally acclaimed leader in the field of medicine and scientist whose research helped pioneer a new type of cancer therapy, died January 7, 2019 at his home in Houston, Texas.

We traveled to San Diego, California, for the 2018 ASH Annual Meeting, where we spoke with several experts across hematologic malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma.

Waun Ki Hong, MD, a trail-blazing physician-scientist, mentor, and 2018 Giant of Cancer Care® in Head and Neck Cancers, whose clinical research innovations led to successful organ-sparing cancer treatment, advanced the field of targeted therapy and launched chemoprevention, died Wednesday at his home in California.

We headed to San Antonio, Texas, for the San Antonio Breast Cancer Symposium, where we spoke to several principal investigators who detailed new applications of novel therapies, surgical intervention strategies, and lifestyle modifications.

We headed to Stanford, California, for a State of the Science Summit on Ovarian Cancer and Soft Tissue Sarcoma, which focused on recent advances made in the treatment landscapes.

Almost half of adult patients with previously treated chronic immune thrombocytopenia achieved major responses with the SYK inhibitor fostamatinib (Tavalisse).

Most pediatric patients with immune thrombocytopenia had rapid and durable platelet responses when treated with the thrombopoietin fusion protein analog romiplostim.

Nonpediatric young adults with stage III/IV Hodgkin lymphoma had significantly better progression-free survival when treated with brentuximab vedotin and conventional chemotherapy compared with standard therapy.

Patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia achieved objective response rates as high as 100% with either of 2 doses of the BTK inhibitor acalabrutinib, results of an open-label phase II trial showed.

The Association of Community Cancer Centers is pleased to announce the hiring of Leigh M. Boehmer, PharmD, BCOP, as Medical Director, Education, for the association’s expanding education initiatives.

African-American patients with early breast cancer had worse outcomes than Caucasian patients following adjuvant therapy, despite having a similar risk of recurrence and receiving similar types of therapy, according to subgroup analysis of the phase III TAILORx trial.

Chemotherapy for breast cancer caused significantly more acute symptoms as compared with endocrine therapy, although the adverse effects of endocrine therapy increased over time.

The combination of palbociclib and trastuzumab demonstrated safety and efficacy in patients with advanced estrogen receptor–positive/HER2-positive breast cancer.

U3-1402, an investigational antibody-drug conjugate targeting HER3, induced objective response in more than 40% of heavily pretreated patients with HER3-expressing breast cancer.

The Association of Community Cancer Centers announced today that it has partnered with Pfizer Global Medical Grants to award more than $1.8 million in funding to 15 projects that are aimed at improving the quality of breast cancer patient care.

We headed to Chicago, Illinois, for a State of the Science Summit on Advanced Non–Small Cell Lung Cancer, which focused on recent updates in the field, particularly data from the 2018 World Conference on Lung Cancer.

The combination of venetoclax and rituximab for relapsed/refractor chronic lymphoblastic leukemia produced high rates of undetectable minimal residual disease, which was associated with prolonged progression-free survival, a new analysis of a randomized trial showed.

Patients with relapsed/refractory chronic lymphoblastic leukemia treated with single-agent venetoclax attained high rates of minimal residual disease in peripheral blood and bone marrow.

The overall survival benefit with quizartinib in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukemia was observed across patient subgroups and reproduced consistently across sensitivity analyses.

The addition of a CD79b-targeted antibody-drug conjugate to bendamustine and rituximab more than doubled overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma.

More than 70% of older patients ineligible for intensive chemotherapy for acute myeloid leukemia had complete responses to venetoclax combined with hypomethylating agents, preliminary results from clinical trials have shown.

Checkpoint inhibition showed promise for augmenting or extending response to chimeric antigen receptor T-cell therapy in some patients with relapsed B-cell acute lymphoblastic leukemia.

The Association of Community Cancer Centers announced the relaunch of the ACCC Immuno-Oncology Institute including an online resource portal for oncology professionals to find practical, proactive strategies for the effective delivery of new and emerging therapies.

Tumor mutational burden has been shown in studies to predict response to immunotherapies in certain types of cancer and is being validated in clinical trials as a biomarker of response.

We headed to Charlotte, North Carolina, for a State of the Science Summit on Genitourinary Cancers, which focused on the evolving paradigms of prostate cancer and renal cell carcinoma.

The treatment options for women with hormone receptor (HR)–positive metastatic breast cancer have evolved rapidly in the past decade, with the introduction of the CDK4 and CDK6 inhibitors representing a major advance.

We headed to Clayton, Missouri for a State of the Science Summit on Hematologic Malignancies, which focused on novel agents in chronic lymphocytic leukemia, advances in acute myeloid leukemia, progress in myeloproliferative neoplasms, and more.

Roswell Park Comprehensive Cancer Center has formed an academic cooperation agreement with the Jagiellonian University (JU) in Kraków, Poland.

We headed to Newport Beach, California, for a State of the Science Summit on Gastrointestinal Cancers, which focused on the evolving paradigms of colorectal cancer, pancreatic cancer, neuroendocrine tumors, gastric cancer, and hepatocellular carcinoma.